http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2596809-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f815b36b41237d931354b4833bf8c9df |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7061 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7069 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P23-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4168 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F13-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L15-16 |
| filingDate | 2005-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c65345c3fcc082562867140a41d2737 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_311fe8960de1469a07255e1c73615486 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32a25d5f27090be546f773e1946acdd0 |
| publicationDate | 2017-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2596809-T3 |
| titleOfInvention | Transdermal drug delivery device that includes an occlusive booster |
| abstract | A transdermal drug delivery system for administering a therapeutically effective amount of drug for a prolonged period of time, in which the drug is selected from the group consisting of amphetamine, d-amphetamine, l-amphetamine, d, l-amphetamine, methamphetamine, prilocaine, benzocaine, butacaine, butamben, butanilicain, corticaine, lidocaine, memantine, pilocarpine / cyclobenzaprine, paroxetine, fluoxetine, duloxetine, imipramine, dedpramine, doxeprine, nortriptylamine, bipheplamine, biphenylamine, protriptylamine, bipropylamine, biprophelamine, biphenylamine Captopril, clonidine, clonazepam, enalapril, ramiprile, haloperidol, ketoprofen, loratadine, methimazole, methylphenidate, methyltestosterone, nicotine, nitroglycerin, pramipexole, ropinirole, hydromorphone, scopolamine, testosterone, and phetratriatin, estradiol, estradiol, estradiol, estradiol, estradiol, estradiol, estradiol, estradiol, estradiol, estradiol, estradiol, estradiol, estradiol, estradiol, estradiol, estradiol, estradiol, estradiol, estradiol, estradiol, estradiol, estradiol, estradiol, estradiol, estradiol, estradiol, estradiol, estradiol, estradiol, estradiol, estradiol, estradiol, phetramine, estradiol Transdermal administration of drugs comprises: (a) a carrier composition q which comprises (i) a pressure sensitive adhesive that includes at least one acrylic based polymer and is present in an amount from 5% to 97% by weight of said transdermal drug delivery system and (ii) 0 , 1% to about 50% by weight of at least one drug for transdermal drug administration, and (b) an occlusive reinforcement layer, wherein said occlusive reinforcement layer is formed of a plurality of layers, in the that a first layer of said reinforcement layer is formed of polyester and a second layer of said reinforcement layer is formed of polyurethane, and in which the occlusive reinforcement layer has a water vapor transmission rate of from about 0, 5 at about 1500 g / m2 / 24 h measured at 40 ° C and 90% relative humidity that is selected to selectively control the transdermal permeation of said drug from said transdermal drug delivery system p To achieve prolonged drug administration for at least seven days. |
| priorityDate | 2004-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 4828.